【健民集团：克立硼罗软膏获批上市】健民集团公告称，公司收到国家药品监督管理局核准签发的《药品注册证书》，研发的克立硼罗软膏获批上市。该药品为化学药品4类，规格2%，属处方药，适应症为3月龄及以上轻度至中度特应性皮炎患者的局部外用治疗。截至2026年8月31日，该药品累计投入研发费用约1127.41万元。本次获批将丰富公司产品线，预计短期内不会对公司业绩产生较大影响，其上市后市场份额存在不确定性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.